Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross J. Baldessarini, D.Sc., M.D.

Co-Author

This page shows the publications co-authored by Ross Baldessarini and Frank Tarazi.
Connection Strength

5.968
  1. Dopamine D4 receptors: beyond schizophrenia. J Recept Signal Transduct Res. 2004 Aug; 24(3):131-47.
    View in: PubMed
    Score: 0.301
  2. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide. 2002 Dec; 7(4):297-300.
    View in: PubMed
    Score: 0.268
  3. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002 May; 161(3):263-70.
    View in: PubMed
    Score: 0.256
  4. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001 May; 297(2):711-7.
    View in: PubMed
    Score: 0.240
  5. Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Res. 2000 Oct 20; 881(1):69-72.
    View in: PubMed
    Score: 0.232
  6. Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. Neuropharmacology. 2000 Aug 23; 39(11):2133-8.
    View in: PubMed
    Score: 0.229
  7. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci Lett. 2000 Jun 23; 287(2):81-4.
    View in: PubMed
    Score: 0.227
  8. Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain. Int J Dev Neurosci. 2000 Feb; 18(1):29-37.
    View in: PubMed
    Score: 0.220
  9. Dopamine D4 receptors: significance for molecular psychiatry at the millennium. Mol Psychiatry. 1999 Nov; 4(6):529-38.
    View in: PubMed
    Score: 0.217
  10. Brain dopamine D(4) receptors: basic and clinical status. Int J Neuropsychopharmacol. 1999 Mar; 2(1):41-58.
    View in: PubMed
    Score: 0.207
  11. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J Neurosci Res. 1999 Feb 15; 55(4):401-10.
    View in: PubMed
    Score: 0.206
  12. Postnatal development of dopamine D1-like receptors in rat cortical and striatolimbic brain regions: An autoradiographic study. Dev Neurosci. 1999; 21(1):43-9.
    View in: PubMed
    Score: 0.204
  13. Effects of hippocampal kainic acid lesions on striatolimbic dopamine D1-, D2-, and D4-like receptors. Neuroscience. 1998 Nov; 87(1):1-4.
    View in: PubMed
    Score: 0.202
  14. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse. 1998 Oct; 30(2):227-35.
    View in: PubMed
    Score: 0.201
  15. Postnatal development of dopamine D4-like receptors in rat forebrain regions: comparison with D2-like receptors. Brain Res Dev Brain Res. 1998 Oct 01; 110(2):227-33.
    View in: PubMed
    Score: 0.201
  16. Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi. Neurosci Lett. 1998 Sep 18; 254(1):21-4.
    View in: PubMed
    Score: 0.200
  17. Effects of hippocampal lesions on striatolimbic ionotropic glutamatergic receptors. Neurosci Lett. 1998 Jun 26; 250(1):13-6.
    View in: PubMed
    Score: 0.197
  18. Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1998 May; 22(4):693-707.
    View in: PubMed
    Score: 0.195
  19. Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience. 1998 Mar; 83(1):169-76.
    View in: PubMed
    Score: 0.193
  20. Regional distribution of dopamine D4 receptors in rat forebrain. Neuroreport. 1997 Nov 10; 8(16):3423-6.
    View in: PubMed
    Score: 0.189
  21. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996 Mar-Apr; 3(6):301-25.
    View in: PubMed
    Score: 0.168
  22. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2007 May-Jun; 17(6-7):448-55.
    View in: PubMed
    Score: 0.089
  23. Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse. 2006 Feb; 59(2):92-100.
    View in: PubMed
    Score: 0.084
  24. Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2005 Sep; 8(3):439-44.
    View in: PubMed
    Score: 0.079
  25. Regulation of working memory by dopamine D4 receptor in rats. Neuropsychopharmacology. 2004 Sep; 29(9):1648-55.
    View in: PubMed
    Score: 0.076
  26. Enhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout mice. J Mol Neurosci. 2004; 22(3):167-78.
    View in: PubMed
    Score: 0.072
  27. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003 Sep; 306(3):1145-51.
    View in: PubMed
    Score: 0.070
  28. Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev. 2003 Apr; 42(1):1-21.
    View in: PubMed
    Score: 0.069
  29. Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res. 2002 Aug 30; 137(2):135-8.
    View in: PubMed
    Score: 0.066
  30. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther. 2002 Jun; 301(3):1097-102.
    View in: PubMed
    Score: 0.065
  31. Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology. 2002 May; 26(5):625-33.
    View in: PubMed
    Score: 0.064
  32. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Psychopharmacology (Berl). 2002 Apr; 161(1):100-6.
    View in: PubMed
    Score: 0.064
  33. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16(1):23-45.
    View in: PubMed
    Score: 0.063
  34. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb; 160(1):92-8.
    View in: PubMed
    Score: 0.063
  35. Role of dopamine D(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology. 2001 Nov; 25(5):624-32.
    View in: PubMed
    Score: 0.062
  36. Nigrostriatal dopaminergic denervation enhances dopamine D(4) receptor binding in rat caudate-putamen. Pharmacol Biochem Behav. 2001 May-Jun; 69(1-2):111-6.
    View in: PubMed
    Score: 0.060
  37. GABA(B) receptors: altered coupling to G-proteins in rats sensitized to amphetamine. Neuroscience. 2000; 101(1):5-10.
    View in: PubMed
    Score: 0.055
  38. Dopamine D(4) receptors in rat forebrain: unchanged with amphetamine-induced behavioral sensitization. Neuroscience. 2000; 97(2):211-3.
    View in: PubMed
    Score: 0.055
  39. Effects of alkylating agents on dopamine D(3) receptors in rat brain: selective protection by dopamine. Brain Res. 1999 Nov 13; 847(1):32-7.
    View in: PubMed
    Score: 0.054
  40. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997 Sep; 17(3):186-96.
    View in: PubMed
    Score: 0.047
  41. Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 01; 19(1):51-3.
    View in: PubMed
    Score: 0.025
  42. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorg Med Chem Lett. 2008 Jul 15; 18(14):3971-3.
    View in: PubMed
    Score: 0.025
  43. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. J Med Chem. 2008 Feb 28; 51(4):983-7.
    View in: PubMed
    Score: 0.024
  44. R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 01; 17(15):4128-30.
    View in: PubMed
    Score: 0.023
  45. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15; 17(2):533-7.
    View in: PubMed
    Score: 0.022
  46. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999 Dec 03; 385(2-3):291-4.
    View in: PubMed
    Score: 0.014
  47. Selective alkylatation of dopamine D2 and D4 receptors in rat brain by N-(p-isothiocyanatophenethyl)spiperone. Neurosci Lett. 1999 Oct 29; 274(3):155-8.
    View in: PubMed
    Score: 0.014
  48. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12; 367(1):139-42.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.